vs
Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and James River Group Holdings, Inc. (JRVR). Click either name above to swap in a different company.
James River Group Holdings, Inc. is the larger business by last-quarter revenue ($167.7M vs $85.1M, roughly 2.0× 4D Molecular Therapeutics, Inc.). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs 19.1%, a 3.7% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 32.4%). 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $-23.6M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs -8.7%).
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
James River Corporation was an American pulp and paper company based in Richmond, Virginia, once the largest paper manufacturer in the world.
FDMT vs JRVR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $85.1M | $167.7M |
| Net Profit | $19.4M | $32.1M |
| Gross Margin | — | — |
| Operating Margin | 17.3% | 14.6% |
| Net Margin | 22.8% | 19.1% |
| Revenue YoY | 8508900.0% | 32.4% |
| Net Profit YoY | 139.1% | 149.5% |
| EPS (diluted) | $0.43 | $0.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $85.1M | $167.7M | ||
| Q3 25 | $90.0K | $172.7M | ||
| Q2 25 | $15.0K | $174.8M | ||
| Q1 25 | $14.0K | $172.3M | ||
| Q4 24 | $1.0K | $126.7M | ||
| Q3 24 | $3.0K | $191.5M | ||
| Q2 24 | $5.0K | $188.3M | ||
| Q1 24 | $28.0K | $201.1M |
| Q4 25 | $19.4M | $32.1M | ||
| Q3 25 | $-56.9M | $1.0M | ||
| Q2 25 | $-54.7M | $4.8M | ||
| Q1 25 | $-48.0M | $9.6M | ||
| Q4 24 | — | $-64.8M | ||
| Q3 24 | $-43.8M | $-39.4M | ||
| Q2 24 | $-35.0M | $7.6M | ||
| Q1 24 | $-32.4M | $15.4M |
| Q4 25 | 17.3% | 14.6% | ||
| Q3 25 | -67983.3% | 1.5% | ||
| Q2 25 | -396373.3% | 4.2% | ||
| Q1 25 | -383007.1% | 9.3% | ||
| Q4 24 | — | -57.0% | ||
| Q3 24 | -1704400.0% | -27.1% | ||
| Q2 24 | -849120.0% | 10.7% | ||
| Q1 24 | -136200.0% | 16.4% |
| Q4 25 | 22.8% | 19.1% | ||
| Q3 25 | -63195.6% | 0.6% | ||
| Q2 25 | -364386.7% | 2.7% | ||
| Q1 25 | -342657.1% | 5.6% | ||
| Q4 24 | — | -51.1% | ||
| Q3 24 | -1461433.3% | -20.6% | ||
| Q2 24 | -699060.0% | 4.0% | ||
| Q1 24 | -115717.9% | 7.7% |
| Q4 25 | $0.43 | $0.59 | ||
| Q3 25 | $-1.01 | $-0.02 | ||
| Q2 25 | $-0.98 | $0.06 | ||
| Q1 25 | $-0.86 | $0.16 | ||
| Q4 24 | — | $-2.44 | ||
| Q3 24 | $-0.79 | $-1.10 | ||
| Q2 24 | $-0.63 | $0.13 | ||
| Q1 24 | $-0.66 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $402.7M | $260.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $505.7M | $538.2M |
| Total Assets | $566.7M | $4.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $402.7M | $260.9M | ||
| Q3 25 | $305.1M | $238.8M | ||
| Q2 25 | $293.2M | $220.0M | ||
| Q1 25 | $321.4M | $279.4M | ||
| Q4 24 | $424.9M | $362.3M | ||
| Q3 24 | $501.9M | $359.8M | ||
| Q2 24 | $541.9M | $672.5M | ||
| Q1 24 | $525.9M | $305.5M |
| Q4 25 | $505.7M | $538.2M | ||
| Q3 25 | $369.0M | $503.6M | ||
| Q2 25 | $420.9M | $492.6M | ||
| Q1 25 | $469.7M | $484.5M | ||
| Q4 24 | $510.6M | $460.9M | ||
| Q3 24 | $552.9M | $530.3M | ||
| Q2 24 | $588.3M | $541.8M | ||
| Q1 24 | $600.6M | $539.5M |
| Q4 25 | $566.7M | $4.9B | ||
| Q3 25 | $424.0M | $5.0B | ||
| Q2 25 | $473.6M | $5.0B | ||
| Q1 25 | $515.7M | $4.9B | ||
| Q4 24 | $560.4M | $5.0B | ||
| Q3 24 | $604.0M | $5.0B | ||
| Q2 24 | $620.1M | $4.7B | ||
| Q1 24 | $629.9M | $5.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.6M | $-18.8M |
| Free Cash FlowOCF − Capex | $28.5M | $-23.6M |
| FCF MarginFCF / Revenue | 33.5% | -14.1% |
| Capex IntensityCapex / Revenue | 0.1% | 2.9% |
| Cash ConversionOCF / Net Profit | 1.47× | -0.59× |
| TTM Free Cash FlowTrailing 4 quarters | $-109.9M | $-17.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.6M | $-18.8M | ||
| Q3 25 | $-46.5M | $34.3M | ||
| Q2 25 | $-43.4M | $25.2M | ||
| Q1 25 | $-47.8M | $-51.5M | ||
| Q4 24 | $-134.6M | $-247.1M | ||
| Q3 24 | $-29.4M | $-269.9M | ||
| Q2 24 | $-30.2M | $-8.7M | ||
| Q1 24 | $-29.1M | $24.1M |
| Q4 25 | $28.5M | $-23.6M | ||
| Q3 25 | $-46.6M | $33.7M | ||
| Q2 25 | $-43.4M | $24.7M | ||
| Q1 25 | $-48.4M | $-52.7M | ||
| Q4 24 | $-138.4M | $-252.0M | ||
| Q3 24 | $-31.2M | $-270.8M | ||
| Q2 24 | $-30.6M | $-9.3M | ||
| Q1 24 | $-29.8M | $23.3M |
| Q4 25 | 33.5% | -14.1% | ||
| Q3 25 | -51765.6% | 19.5% | ||
| Q2 25 | -289620.0% | 14.1% | ||
| Q1 25 | -345635.7% | -30.6% | ||
| Q4 24 | -13837100.0% | -198.9% | ||
| Q3 24 | -1038966.7% | -141.4% | ||
| Q2 24 | -611840.0% | -4.9% | ||
| Q1 24 | -106421.4% | 11.6% |
| Q4 25 | 0.1% | 2.9% | ||
| Q3 25 | 101.1% | 0.4% | ||
| Q2 25 | 440.0% | 0.3% | ||
| Q1 25 | 4507.1% | 0.7% | ||
| Q4 24 | 378600.0% | 3.9% | ||
| Q3 24 | 59266.7% | 0.4% | ||
| Q2 24 | 6980.0% | 0.3% | ||
| Q1 24 | 2535.7% | 0.4% |
| Q4 25 | 1.47× | -0.59× | ||
| Q3 25 | — | 33.61× | ||
| Q2 25 | — | 5.29× | ||
| Q1 25 | — | -5.38× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.14× | ||
| Q1 24 | — | 1.56× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FDMT
Segment breakdown not available.
JRVR
| Excess And Surplus Lines | $156.7M | 93% |
| Specialty Admitted Insurance | $10.9M | 7% |
